The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
On Wednesday 21 March 2018 during an oral abstract session at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Arnon Nagler on behalf of his colleagues, presented results of a multi-center study with the use of vedolizumab (Vd) in severe steroid resistant (SR) gatrointestinal (GI) GvHD.
Professor Nagler started his talk by introducing Vd and highlighted its importance in steroid resistant aGvHD which is a life-threating complication of allogeneic-stem cell transplantation (allo-SCT). Vd is a gut-selective integrin blocker that targets the binding of integrin α4β7 to Mad CAM-1, blocking the homing of T cells to the GI endothelium and thus it may be beneficial for the treatment of intestinal GvHD.
Professor Nagler concluded his talk by stating that “this data suggests that targeting integrin α4β7 may ameliorate severe SR GI aGvHD, especially when Vd is started early, as second line treatment after steroids failure.” He further added that “the role of Vd currently explore in a prospective clinical trial.”
References